Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, CorMedix Inc’s stock clocked out at $10.58, down -1.40% from its previous closing price of $10.73. In other words, the price has decreased by -$1.40 from its previous closing price. On the day, 1.89 million shares were traded. CRMD stock price reached its highest trading level at $10.869 during the session, while it also had its lowest trading level at $10.385.
Ratios:
To gain a deeper understanding of CRMD’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.33 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 27.16. For the most recent quarter (mrq), Quick Ratio is recorded 7.52 and its Current Ratio is at 7.82. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 30, 2025, initiated with a Buy rating and assigned the stock a target price of $20.
On March 07, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $18.Leerink Partners initiated its Outperform rating on March 07, 2025, with a $18 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 12 ’25 when DUNTON ALAN W sold 10,000 shares for $13.13 per share. The transaction valued at 131,300 led to the insider holds 40,250 shares of the business.
Todisco Joseph sold 50,000 shares of CRMD for $650,000 on Sep 12 ’25. The Chief Executive Officer now owns 509,496 shares after completing the transaction at $13.00 per share. On Sep 12 ’25, another insider, DUNTON ALAN W, who serves as the Director of the company, bought 10,000 shares for $13.10 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRMD now has a Market Capitalization of 825861056 and an Enterprise Value of 599509888. As of this moment, CorMedix’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.17, and their Forward P/E ratio for the next fiscal year is 4.33. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.80 while its Price-to-Book (P/B) ratio in mrq is 3.58. Its current Enterprise Value per Revenue stands at 4.935 whereas that against EBITDA is 12.025.
Stock Price History:
The Beta on a monthly basis for CRMD is 1.82, which has changed by 0.048562884 over the last 52 weeks, in comparison to a change of 0.1443547 over the same period for the S&P500. Over the past 52 weeks, CRMD has reached a high of $17.43, while it has fallen to a 52-week low of $5.60. The 50-Day Moving Average of the stock is -13.36%, while the 200-Day Moving Average is calculated to be -4.69%.
Shares Statistics:
It appears that CRMD traded 3.30M shares on average per day over the past three months and 2090750 shares per day over the past ten days. A total of 74.62M shares are outstanding, with a floating share count of 69.94M. Insiders hold about 10.75% of the company’s shares, while institutions hold 44.36% stake in the company. Shares short for CRMD as of 1759190400 were 15564623 with a Short Ratio of 4.71, compared to 1756425600 on 11886496. Therefore, it implies a Short% of Shares Outstanding of 15564623 and a Short% of Float of 20.14.
